Cytokinetics Inc (CYTK) Stocks Experience Steady decrease to Close at $76.94

Cytokinetics Inc (NASDAQ: CYTK) closed the day trading at $76.94 down -2.53% from the previous closing price of $78.94. In other words, the price has decreased by -$2.00 from its previous closing price. On the day, 1883944 shares were traded. CYTK stock price reached its highest trading level at $79.77 during the session, while it also had its lowest trading level at $76.52.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.


For a better understanding of CYTK, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.22 and its Current Ratio is at 7.22.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 24, 2024, Downgraded its rating to Neutral and sets its target price to $92 from $61 previously.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 06 when Malik Fady Ibraham sold 32,605 shares for $79.30 per share. The transaction valued at 2,585,496 led to the insider holds 142,973 shares of the business.

Blum Robert I sold 12,500 shares of CYTK for $994,625 on Jan 31. The President & CEO now owns 441,797 shares after completing the transaction at $79.57 per share. On Jan 19, another insider, Blum Robert I, who serves as the President & CEO of the company, sold 12,500 shares for $81.42 each. As a result, the insider received 1,017,750 and left with 441,797 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 7.55B and an Enterprise Value of 7.76B. For the stock, the TTM Price-to-Sale (P/S) ratio is 964.70. Its current Enterprise Value per Revenue stands at 992.88 whereas that against EBITDA is -16.77.

Stock Price History:

Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is 66.35, while the 200-Day Moving Average is calculated to be 42.32.

Shares Statistics:

Over the past 3-months, CYTK traded about 0.52 shares per day on average, while over the past 10 days, CYTK traded about 2M shares per day. A total of 94.83M shares are outstanding, with a floating share count of 93.63M. Insiders hold about 4.51% of the company’s shares, while institutions hold 109.04% stake in the company. Shares short for CYTK as of Jan 31, 2024 were 13.58M with a Short Ratio of 3.74, compared to 15.08M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 13.85% and a Short% of Float of 23.37%.

Earnings Estimates

Current recommendations for the stock of the company come from 17 analysts. On average, analysts expect EPS of -$0.97 for the current quarter, with a high estimate of -$0.38 and a low estimate of -$1.47, while EPS last year was -$1.45. The consensus estimate for the next quarter is -$1, with high estimates of -$0.59 and low estimates of -$1.44.

Analysts are recommending an EPS of between -$4.39 and -$5.41 for the fiscal current year, implying an average EPS of -$4.97. EPS for the following year is -$4.53, with 17 analysts recommending between -$2.13 and -$6.27.

Revenue Estimates

A total of 17 analysts have provided revenue estimates for CYTK’s current fiscal year. The highest revenue estimate was $57.06M, while the lowest revenue estimate was $5.86M, resulting in an average revenue estimate of $19.05M. In the same quarter a year ago, actual revenue was $94.59M, down -79.90% from the average estimate.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular